Resilient Pharmaceuticals Resubmits MDMA Therapy Application

The company seeks FDA approval for MDMA-assisted therapy to treat post-traumatic stress disorder in the United States.

Updated on Oct. 23, 2026 in Substance Abuse

Resilient Pharmaceuticals Resubmits MDMA Therapy Application

Live Poll

Should the FDA approve MDMA-assisted therapy for treating PTSD patients?

Resilient Pharmaceuticals resubmitted its application for FDA approval of MDMA-assisted therapy in August 2026. The filing follows a prior rejection from the FDA in August 2024 regarding clinical trial data.

Why it matters

The FDA initially rejected the application due to concerns regarding clinical trial data reliability and therapy effectiveness. Advocates note that even with potential approval, a shortage of qualified therapists remains a significant barrier to patient access.

The application cites research from groups including the Veterans Affairs department to support its efficacy claims. An estimated 13 million people in the United States currently live with PTSD.

The players

Resilient Pharmaceuticals

This company, formerly known as Lykos Therapeutics, is the primary developer pursuing FDA approval for MDMA-assisted therapy.

President Donald Trump

As the current President of the United States, he signed an executive order in April 2026 to increase federal support for psychedelic research.

Eli Lilly

This major pharmaceutical corporation expanded its reach in the sector by acquiring AtaiBeckley for $2.8 billion in July 2026.

MAPS

The Multidisciplinary Association for Psychedelic Studies is a research organization scheduling therapist training for December 2026.

The details

The FDA permitted the current application to proceed without requiring a new Phase 3 study, opting to review existing data instead. Research from the Department of Defense is also ongoing, examining the use of MDMA-assisted therapy for active duty soldiers.

In 2021, MAPS conducted a clinical trial for MDMA-assisted therapy.
In August 2024, the FDA rejected the MDMA application from Lykos Therapeutics.
In April 2026, President Trump signed an executive order on psychedelic research.
In July 2026, Eli Lilly acquired AtaiBeckley for $2.8 billion.
In August 2026, Resilient Pharmaceuticals resubmitted its FDA application.

Health Landscape

The current push for MDMA-assisted therapy follows President Trump's April 2026 executive order on psychedelic research, which mandates increased federal prioritization of the field. This marks a shift toward integrating previously prohibited substances into standard psychiatric care protocols.

The FDA could approve the therapy by early 2027, potentially expanding treatment options for those suffering from PTSD. However, patients may still face challenges accessing treatment due to a documented shortage of licensed and trained therapists.

The takeaway

While the FDA process is moving forward, the integration of psychedelic-based treatments into the American healthcare system remains a complex regulatory and logistical challenge. Patients should consult with specialized mental health providers to stay informed on emerging clinical options.

What happens next

MAPS is scheduled to conduct its first training program for MDMA-assisted therapy in December 2026, and the FDA could potentially issue an approval decision as early as January 2027.